April 16, 2021 Oncopeptides submits application for conditional marketing authorization of melflufen in the EU
April 12, 2021 Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis
April 10, 2021 Fusion Pharmaceuticals Announces Preclinical Combination Data Demonstrating Enhanced Efficacy In Multiple Preclinical Tumor Models